Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
Chronic disease patients seek online support and information, and show little love for branded websites.
Contrary to a claim by a Kentucky Republican congressman that he was assured by FDA that it would not approve new opioids unless they had abuse-deterrent formulations, the agency says it never made such a commitment.
Research suggests ADHD is becoming a regular fixture in adolescence. At the same time, publishers and startups have developed increasingly complex tools to separate patients from abusers.
Getting to an integrated mar-comms model isn't easy. Addressing your agency's lack of digital skills is a good start.
AstraZeneca has been awarded $76 million in damages in a ruling over Apotex's sales of a generic version of Prilosec.
Impax Laboratories announced that it has reached an agreement with Purdue Pharma to settle patent litigation surrounding Impax's generic version of OxyContin.
Following a Warning Letter from the FDA, 23andMe has stopped marketing its DNA test.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
Missed MM&M's recent Skill Sets Live event on Multi-Screen Marketing? We're now giving you a second chance to get up to speed! Click here to access this insightful e-book with all the key take-aways.